- €480.94m
- €426.71m
- €501.11m
Brief: Boiron Q4 Revenues Down 8.9% At EUR 143.4 Mln
Brief: Boiron Expect Decrease In Sales And Earnings In 2020
Brief: Boiron H1 Operating Income Down At 1.5 Million Euros
Brief: Boiron H1 Revenue Down EUR 253.6 Mln, Sees Decline In 2020 Results
Brief: Boiron Q1 Revenue Up At EUR 156.6 Mln, Sees Drop In 2020 Turnover
Brief: Boiron Reports Q4 Sales Of 157.3 Million Euros, Down 6.3%
Brief: Boiron Q3 Revenue Down At 143.1 Million Euros
Brief: Boiron And Lehning Laboratories File Two Appeals Against Homeopathy Health Insurance Orders
French and Benelux stocks-Factors to watch on Sept 5
Brief: Boiron H1 Net Result Turns To Loss Of 0.4 Million Euros
Brief: Boiron H1 Sales Drops To 256.7 Million Euros
France will end healthcare refunds for homeopathic drugs (updated)
French health watchdog recommends ending reimbursement for homeopathic drugs
Brief: Boiron: HAS Maintains Unfavorable Opinion Regarding Reimbursement Of Homeopathic Medicines
Brief: Boiron Sees 60% Of Its Activity Directly Affected By Change Of Reimbursement Rate Of Homeopathic Medicines
Brief: Boiron asks regulator to suspend trading in shares after media leaks
Boiron: Shares drop at resumption of trading
Brief: Boiron Trading Of Shares Will Resume On May 20, 2019
French and Benelux stocks-Factors to watch